A UNIQUE IN VIVO ASSAY FOR YOUR ONCOLOGY DRUG CANDIDATES Target Validation Efficacy and Toxicity Evaluation Arnaud Peyronnier Business Development Manager.

Slides:



Advertisements
Similar presentations
The Drug Discovery Process
Advertisements

The Role of Drug Metabolism Studies in Optimizing Drug Candidates
Targeted Cancer Therapeutics, LLC Investor Presentation.
Clinical Trial Design Considerations for Therapeutic Cancer Vaccines Richard Simon, D.Sc. Chief, Biometric Research Branch, NCI
Clinical Trials — A Closer Look. The Food and Drug Administration (FDA) is the main consumer watchdog for numerous products: Drugs and biologics (prescription.
Non-Small-Cell Lung Cancer Leading cause of cancer-related mortality in the US Current Therapies: –“ Despite great efforts, only minor gains” Traynor.
Clinical Division of Oncology Department of Medicine I Medical University of Vienna, Austria Drug Development.
First HAYAT Annual Patients Forum – 21 st March 2010 – SAS, Kuwait First HAYAT Annual Patients Forum 21 st March 2010 Al Hashimi II Ballroom – SAS Hotel.
Provider of Global Contract Research Services Accelerating Preclinical Research, Drug Discovery & Therapeutics Altogen Labs 4020 S Industrial Dr Suite.
A new antivirulence approach against pathogenic bacteria A new antivirulence approach against pathogenic bacteria May 2005 Sonia Escaich - President &
Oncolytic Viruses “Onco” = cancer “Lytic” = killing An innovative cancer therapy that seeks to harness the natural properties of viruses to aid in the.
ONCOLOGY Drug Development Fadi Sami Farhat, MD ONCOLOGY Drug Development Fadi Sami Farhat, MD Hematology Oncology
Decreased Risk of Radiation Pneumonitis With Coincident Concurrent Use Of Angiotensin- Converting Enzyme Inhibitors In Patients Receiving Lung Stereotactic.
Preclinical Guidelines: Development of Radioprotective/Mitigative Agents Departments of Dermatology & Radiation Oncology University of Rochester Medical.
1 Statistics in Drug Development Mark Rothmann, Ph. D.* Division of Biometrics I Food and Drug Administration * The views expressed here are those of the.
Tumor Markers American cancer society British Journal of Cancer By B.Heidari.
Unit 15: Screening. Unit 15 Learning Objectives: 1.Understand the role of screening in the secondary prevention of disease. 2.Recognize the characteristics.
The Future of Chemical Toxicity Testing in the U.S.
Dr Mahendra Deonarain, Chief Science Officer Antibody Fragment Drug Conjugates (FDCs) Breakthrough ADC therapy BioTrinity April.
RISE Honors Seminar 2014 Ronald Doll RISE Dept. S-332 X 3168 Training – Synthetic Organic Chemist (Ph.D. Duke Univ.) - National Institute.
Altogen Biosystems offers the 786-O Transfection Reagent among a host of 100+ cell line specific In Vitro Transfection Kits. 786-O Transfection Reagent.
Division of Cancer Treatment and Diagnosis Presented By: Michael Difilippantonio, Ph.D. October 1, 2015.
APPLICATIONS OF CYTOTOXICITY
Telephone    Provider of Global Contract Research Services Accelerating Preclinical Research, Drug Discovery.
Uncontrolled Cell Division and Differentiation
Telephone    Provider of Global Contract Research Services Accelerating Preclinical Research, Drug Discovery.
Telephone    Provider of Global Contract Research Services Accelerating Preclinical Research, Drug Discovery.
Telephone    Provider of Global Contract Research Services Accelerating Preclinical Research, Drug Discovery.
Telephone    Provider of Global Contract Research Services Accelerating Preclinical Research, Drug Discovery.
Telephone    Provider of Global Contract Research Services Accelerating Preclinical Research, Drug Discovery.
Telephone    Provider of Global Contract Research Services Accelerating Preclinical Research, Drug Discovery.
Telephone    Provider of Global Contract Research Services Accelerating Preclinical Research, Drug Discovery.
Telephone    Provider of Global Contract Research Services Accelerating Preclinical Research, Drug Discovery.
Telephone    Provider of Global Contract Research Services Accelerating Preclinical Research, Drug Discovery.
Telephone    Provider of Global Contract Research Services Accelerating Preclinical Research, Drug Discovery.
Telephone    Provider of Global Contract Research Services Accelerating Preclinical Research, Drug Discovery.
Telephone    Provider of Global Contract Research Services Accelerating Preclinical Research, Drug Discovery.
Telephone    Provider of Global Contract Research Services Accelerating Preclinical Research, Drug Discovery.
Telephone    Provider of Global Contract Research Services Accelerating Preclinical Research, Drug Discovery.
Telephone    Provider of Global Contract Research Services Accelerating Preclinical Research, Drug Discovery.
Telephone    Provider of Global Contract Research Services Accelerating Preclinical Research, Drug Discovery.
Telephone    Provider of Global Contract Research Services Accelerating Preclinical Research, Drug Discovery.
Telephone    Provider of Global Contract Research Services Accelerating Preclinical Research, Drug Discovery.
Figure 1 Underreporting of treatment-related toxicities by physicians, relative to patients with either advanced-stage lung cancer, or early-stage breast.
Telephone    Provider of Global Contract Research Services Accelerating Preclinical Research, Drug Discovery.
Telephone    Provider of Global Contract Research Services Accelerating Preclinical Research, Drug Discovery.
Telephone    Provider of Global Contract Research Services Accelerating Preclinical Research, Drug Discovery.
Telephone    Provider of Global Contract Research Services Accelerating Preclinical Research, Drug Discovery.
Telephone    Provider of Global Contract Research Services Accelerating Preclinical Research, Drug Discovery.
Telephone    Provider of Global Contract Research Services Accelerating Preclinical Research, Drug Discovery.
Telephone    Provider of Global Contract Research Services Accelerating Preclinical Research, Drug Discovery.
Telephone    Provider of Global Contract Research Services Accelerating Preclinical Research, Drug Discovery.
Telephone    Provider of Global Contract Research Services Accelerating Preclinical Research, Drug Discovery.
Telephone    Provider of Global Contract Research Services Accelerating Preclinical Research, Drug Discovery.
Telephone    Provider of Global Contract Research Services Accelerating Preclinical Research, Drug Discovery.
Telephone    Provider of Global Contract Research Services Accelerating Preclinical Research, Drug Discovery.
Telephone    Provider of Global Contract Research Services Accelerating Preclinical Research, Drug Discovery.
Telephone    Provider of Global Contract Research Services Accelerating Preclinical Research, Drug Discovery.
Telephone    Provider of Global Contract Research Services Accelerating Preclinical Research, Drug Discovery.
Telephone    Provider of Global Contract Research Services Accelerating Preclinical Research, Drug Discovery.
Telephone    Provider of Global Contract Research Services Accelerating Preclinical Research, Drug Discovery.
Telephone    Provider of Global Contract Research Services Accelerating Preclinical Research, Drug Discovery.
Ipsen Ethics & Compliance - Confidential - Only for internal use
Telephone    Provider of Global Contract Research Services Accelerating Preclinical Research, Drug Discovery.
Telephone    Provider of Global Contract Research Services Accelerating Preclinical Research, Drug Discovery.
Telephone    Provider of Global Contract Research Services Accelerating Preclinical Research, Drug Discovery.
Telephone    Provider of Global Contract Research Services Accelerating Preclinical Research, Drug Discovery.
Telephone    Provider of Global Contract Research Services Accelerating Preclinical Research, Drug Discovery.
Overview of cancer genetics in the SMP1 cohort: lung cancer (A), breast cancer (B), colorectal adenocarcinoma (except mucinous subtype) (C), prostate cancer.
MGA271 mediates in vitro ADCC across a panel of ATCC cancer cell lines exhibiting a range of B7-H3 expression. MGA271 mediates in vitro ADCC across a panel.
Presentation transcript:

A UNIQUE IN VIVO ASSAY FOR YOUR ONCOLOGY DRUG CANDIDATES Target Validation Efficacy and Toxicity Evaluation Arnaud Peyronnier Business Development Manager +33 (0) BioTrinity 2016 – Company Showcase – Tuesday 26 April 2016

2 Fast Sensitive Reliable Affordable 2 OUR MISSION: Radically increased productivity in drug discovery INOVOTION has developed a unique technology dedicated to early in vivo EFFICACY and TOXICITY evaluation of anti-cancer drugs. We propose FAST, SENSITIVE, RELIABLE and AFFORDABLE in vivo assays to evaluate anti-cancer molecules. Most drug discovery costs are for low value molecules, in preclinical tests. The lead validation/optimization and preclinical phases are the most expensive and the less productive. INOVOTION allows chemists and biologists to: - significantly improve the productivity of their drug discovery efforts - decrease risk in the preclinical phases - help make Go/No Go decisions

3 Fast Sensitive Reliable Affordable 3 INOVOTION: Early elimination of low value molecules Nb molecules in vitro preclinical A new step to eliminate low value molecules Decrease the risk in pre-clinical phases Rapid Go/No Go decisions Efficacy and Toxicity Evaluation An early and informative evaluation of your molecules

4 Fast Sensitive Reliable Affordable 4 Analysis TumorNodules OUR TECHNOLOGY Human Tumor Cell Grafts Treatment Period Tumoral Development Embryo Development days Tumor Upper CAM Lower CAM Vessels Target Validation Efficacy and Toxicity Evaluation

5 Fast Sensitive Reliable Affordable 5 Classical preclinical models INOVOTIONAvantages 2-3 months1 month Fast results just one month for your study 1,000 units of drug1 unit of drug High sensitivity requires minute amounts of your compounds test points test points Strong reliability high statistical significance - low p value Yes In vivo assays but no animal testing Affordable costs less than comparable techniques Other advantages: Early stage evaluation, to eliminate low value molecules before the mouse studies Great predictivity with the same human cancer cell lines as your other preclinical models MULTIPLE BENEFITS

6 Fast Sensitive Reliable Affordable 6 Compound types Small Molecules Peptides Antibodies Proteins Natural compounds Viruses Nanostructures Treatments types Compound by itself Synergetic effects Sequential effects Cell lines Standard cell lines (ATCC) Wild type or genetically modified Patient cells Cell lines panel INOVOTION ASSAYS: Large range of possibilities

7 Fast Sensitive Reliable Affordable 7 Colon Adenocarcinoma Rhabdomyosarcoma Melanoma Glioma OUR STANDARD OFFERS Efficacy and Toxicity Evaluation 4 experimental groups: Vehicle Reference compound Test compound dose 1 Test compound dose 2 Target Validation 4 experimental groups: Wild type cell line Modified cell line 1 Modified cell line 2 Modified cell line 3 YOUR RESULTS IN JUST 1 MONTH Human Tumors Cervix Adenocarcinoma Breast Adenocarcinoma Lung Carcinoma Pancreas Carcinoma Prostatic Adenocarcinoma Hepatocellular Carcinoma Adrenal Gland Carcinoma Kidney Adenocarcinoma

8 Fast Sensitive Reliable Affordable 8 INOVOTION's technology was created in 2009 by Prof. Jean Viallet (founder). Our technology is the result of 5 years of R&D and more than 180 studies involving academic labs and biotech pharmaceutical companies. We are a spin-off created in 2014, emanating from the IAB Cancer Center, Grenoble Alpes University (France). Our independent labs are located in Biopolis on the Grenoble Medical Campus. ABOUT US Customer Publications: MikaelianI, et al. Cancer Research KroissA, et al. Oncogene Al DhaheriY, et al. PLoSOne Prudent R, et al. Br J Pharmacol El Hasasna H, et al. Sci Rep

9 Fast Sensitive Reliable Affordable 9 OUR REFERENCES: More than 180 studies ECDYSIS PHARMA

10 Fast Sensitive Reliable Affordable 10 Test your compound on 10 cancers! Don’t miss any valuable molecules SPECIAL OFFER: April 15 th to June 15 th Lung Breast Cervix Liver Colon ProstateGlioma Melanoma Adrenal gland Kidney Pancreas Rhabdomyosarcoma 30% discount Multi-Cancer Screening

11 Fast Sensitive Reliable Affordable 11 CONTACT US: Save on your R&D Time! Our LabsINOVOTION Biopolis - 5 Av. du Grand Sablon 38700, La Tronche France Customer Contact Arnaud Peyronnier (direct) (cell) Follow us on Target Validation Efficacy and Toxicity Evaluation Multi-Cancer Screening 30% discount